目的:对BiPAP呼吸机在慢性阻塞性肺疾病并发重型呼吸衰竭治疗中的应用效果进行探讨。方法:选择接受无创通气治疗的慢性阻塞性肺疾病并发重型呼吸衰竭患者60例,通过随机分组的形式,将患者分成A组与B组,每组30例。其中B组患者给予药物、...目的:对BiPAP呼吸机在慢性阻塞性肺疾病并发重型呼吸衰竭治疗中的应用效果进行探讨。方法:选择接受无创通气治疗的慢性阻塞性肺疾病并发重型呼吸衰竭患者60例,通过随机分组的形式,将患者分成A组与B组,每组30例。其中B组患者给予药物、吸氧治疗等基本治疗方法,A组30例患者则是在B组治疗的基础上联合BiPAP呼吸机无创通气治疗,密切监测所有病患在治疗前后的血气研究中PaCO2、pH值、PaO2等指标。结果:采用BiPAP无创通气治疗的A组患者,其疗后5 h PaO2明显升高(P<0.05),PaCO2有所降低(P>0.05),且相比于治疗前和B组,其疗后1 d PaCO2、pH值、PaO2等指标差异有统计学意义(P<0.05)。B组疗后1 d PaO2有明显升高(P<0.05),PaCO2与pH值虽有所改善,但直至2 d后PaCO2才改善显著(P<0.05)。结论:BiPAP呼吸机在慢性阻塞性的肺疾病并发重型呼吸衰竭治疗中的应用效果显著,值得在临床上广泛推广及应用。展开更多
Chronic obstructive pulmonary disease （COPD） is the most common chronic airway disease affecting Chinese population and it ranks number tour leading cause of death. The high mortality and morbidity, increased preval...Chronic obstructive pulmonary disease （COPD） is the most common chronic airway disease affecting Chinese population and it ranks number tour leading cause of death. The high mortality and morbidity, increased prevalence, significant loss of labor, and high medical expenditure warrants attention from the health organization and society to standardize the diagnosis and treatment of COPD. Overall COPD treatment efficacy has been significantly improved with application of long activating bronchial dilator （LABD）, due to the imbalance and geographically different distribution of medical resource and education, standardized treatment under COPD guideline remain the major protocol in a long time period in the future.展开更多
文摘目的:对BiPAP呼吸机在慢性阻塞性肺疾病并发重型呼吸衰竭治疗中的应用效果进行探讨。方法:选择接受无创通气治疗的慢性阻塞性肺疾病并发重型呼吸衰竭患者60例,通过随机分组的形式,将患者分成A组与B组,每组30例。其中B组患者给予药物、吸氧治疗等基本治疗方法,A组30例患者则是在B组治疗的基础上联合BiPAP呼吸机无创通气治疗,密切监测所有病患在治疗前后的血气研究中PaCO2、pH值、PaO2等指标。结果:采用BiPAP无创通气治疗的A组患者,其疗后5 h PaO2明显升高(P<0.05),PaCO2有所降低(P>0.05),且相比于治疗前和B组,其疗后1 d PaCO2、pH值、PaO2等指标差异有统计学意义(P<0.05)。B组疗后1 d PaO2有明显升高(P<0.05),PaCO2与pH值虽有所改善,但直至2 d后PaCO2才改善显著(P<0.05)。结论:BiPAP呼吸机在慢性阻塞性的肺疾病并发重型呼吸衰竭治疗中的应用效果显著,值得在临床上广泛推广及应用。
文摘Chronic obstructive pulmonary disease （COPD） is the most common chronic airway disease affecting Chinese population and it ranks number tour leading cause of death. The high mortality and morbidity, increased prevalence, significant loss of labor, and high medical expenditure warrants attention from the health organization and society to standardize the diagnosis and treatment of COPD. Overall COPD treatment efficacy has been significantly improved with application of long activating bronchial dilator （LABD）, due to the imbalance and geographically different distribution of medical resource and education, standardized treatment under COPD guideline remain the major protocol in a long time period in the future.
